As of Thursday close, Cognition Therapeutics Inc.’s (NASDAQ:CGTX) stock was up $1.38, moving up 62.16 percent to $3.60. The average number of shares traded per day over the past five days has been 4,317,520 shares. 2 times new highs have been achieved over the past 5 days, with a $1.58 gain in that time frame. In the last twenty days, the average volume was 1,105,775, while in the previous 50 days, it was 465,836.
Since last month, CGTX stock rose 46.94%. Shares of the company fell to $1.76 on 07/27/22, the lowest level in the past month. Since the beginning of this year, CGTX’s stock price has dropped by -43.04% or -$2.72, and marked a new high 2 times. However, the stock has declined by -73.91% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Cognition Therapeutics Inc. (CGTX) last reported insider trading activity 296 days ago on Oct 13. Wallace Peggy, the Director of the company, purchased of 3,000 shares for $12.00 on Oct 13. It resulted in a $36,000 investment by the insider.
In the three months ended March 30, Cognition Therapeutics Inc.’s quick ratio stood at 7.40, while its current ratio was 7.40, showing that the company is able to pay off its debt. Based on annual data, CGTX earned $0.89 million in gross profit and brought in $28.6 million in revenue.
While analysts expected Cognition Therapeutics Inc. to report -$0.29 quarterly earnings, the actual figure was -$0.17 per share, beating the consensus estimate by 41.40%. During the quarter, the company generated -$9.36 million in EBITDA. The liabilities of Cognition Therapeutics Inc. were 9.96 million at the end of its most recent quarter ended March 30, and its total debt was $1.4 million. The value of shareholders’ equity is $22.6 million.
This quick technical analysis looks at Cognition Therapeutics Inc.’s (CGTX) price momentum. With a historical volatility rate of 246.97%, the RSI 9-day stood at 84.96% on 04 August.
With respect to its five-day moving average, the current Cognition Therapeutics Inc. price is up by +78.22% percent or $1.58. At present, CGTX shares trade +57.20% above its 20-day simple moving average and +33.83% percent above its 100-day simple moving average. However, the stock is currently trading approximately +38.46% above its SMA50 and -70.00% below its SMA200.
Stochastic coefficient K was 50.44% and Stochastic coefficient D was 46.90%, while ATR was 0.74. Given the Stochastic reading of 40.80% for the 14-day period, the RSI (14) reading has been calculated as 77.41%. As of today, the MACD Oscillator reading stands at 0.40, while the 14-day reading stands at 0.46.
Oppenheimer launched its rating on Cognition Therapeutics Inc. (NASDAQ: CGTX) to an Outperform in a note to investors on November 03, 2021. Cognition Therapeutics Inc. (CGTX) has been rated Buy by analysts. According to 0 brokerage firms, CGTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Cognition Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $16.50, the current consensus forecast for the stock is $15.00 – $18.00. Based on these forecasts, analysts predict Cognition Therapeutics Inc. (CGTX) will achieve an average price target of $16.50.